Characterization of BRAF Thr599dup Mutation as a Targetable Driver Mutation Identified in Lung Adenocarcinoma by Comprehensive Genomic Profiling.

PURPOSE: Understanding the function of BRAF mutants is crucial for determining the best treatment strategy. This study aimed to characterize a rare BRAF variant, BRAF ^Thr599dup, which was identified in a patient with lung adenocarcinoma (LUAD) by comprehensive genomic profiling. MATERIALS AND METHODS: We report a case of LUAD with BRAF ^Thr599dup treated with dabrafenib and trametinib. We conditionally expressed wild-type BRAF, BRAF^V600E, or BRAF^Thr599dup in Ba/F3 cells and BEAS-2B cells. Ba/F3 cells carrying double-mutant BRAF (BRAF^{Thr599dup/R509H}, BRAF^V600E/R509H, or BRAF^K601E/R509H) that lacked the dimerizing ability were also established. Knockout of endogenous BRAF or CRAF in Ba/F3-BRAF^Thr599dup cells and Ba/F3-BRAF^V600E cells was performed using the CRISPR/Cas9 system. Cell viability, mitogen-activated protein kinase (MAPK) signaling activity, and sensitivity to dabrafenib and trametinib were evaluated. RESULTS: The patient was revealed to have BRAF ^Thr599dup-positive tumor cells as a predominant clone, and dabrafenib and trametinib treatment showed modest efficacy. In Ba/F3 cells, both BRAF^Thr599dup and BRAF^V600E similarly caused interleukin-3–independent proliferation and activated the MAPK pathway. Moreover, BRAF^Thr599dup and BRAF^V600E similarly caused a significant increase in the anchorage-independent growth ability of BEAS-2B cells. Along with Ba/F3-BRAF^V600E cells, Ba/F3-BRAF^Thr599dup cells were highly sensitive to a monomer-specific BRAF inhibitor, dabrafenib, with a half-maximal inhibitory concentration value of 29.7 nM. In the absence of wild-type BRAF, wild-type CRAF, or an intact dimer interface, the ability to induce oncogenic addiction and MAPK pathway activation in Ba/F3-BRAF^Thr599dup cells was not affected, which was in contrast to the findings in the BRAF^K601E/R509H double-mutant model. CONCLUSION: BRAF ^Thr599dup is a potent driver oncogene that activates the MAPK pathway without the requirement for dimerization in vitro. Because BRAF ^Thr599dup has been recurrently reported across various cancer types, our findings should be further investigated both mechanistically and clinically. This study characterizes BRAFThr599dup as a potent driver oncogene that is categorized as a class I BRAF mutation. [ABSTRACT FROM AUTHOR]